West Pharmaceutical Services received a Zacks Rank #1 (Strong Buy) upgrade this week, driven by a consensus upward revision of its full-year earnings estimates. Over the past 30 days, analysts have raised their fiscal 2026 EPS forecasts by an average of 4.2%. This positive shift follows management’s disclosure of a 12% year-over-year increase in manufacturing capacity utilization at its drug containment facilities, signaling stronger profitability potential in the second half of the year. Investors are also encouraged by the company’s 8% rise in specialty component orders during the most recent quarter, underscoring robust demand from vaccine and injectable drug producers.

After a 9.7% decline over the past four weeks, technical metrics indicate that WST has entered oversold territory, with its 14-day relative strength index falling below 30. The stock’s 50-day moving average now sits approximately 7% above current levels, setting up a possible mean reversion opportunity. Wall Street analysts remain broadly constructive: of the 15 firms covering WST, 11 have maintained or raised their ratings in the last month. Combined with a 3.5% increase in average price targets over the same period, these factors point to a growing likelihood of a near-term rebound for the shares.